Cite
HARVARD Citation
Le, D. et al. (n.d.). Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal for immunotherapy of cancer. p. . [Online].